Biointron Insights: Antibody Industry Report (Q3 2025 Insights, Trends & Analysis)

Biointron’s Q3 2025 antibody industry report aims to explore the events and trends of the biopharmaceutical industry in July, August, and September. This quarter, 2 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: both from China.

1. Firsekibart (Jin Beixin)

2. Suvemcitug (Enzheshu)

Q3 2025 saw various acquisitions, collaborations, and licensing agreements of up to US$8 billion. Investment into antibody drug startups has focused on artificial intelligence platforms and antibody bispecific formats.

Gain exclusive insights into current trends such as:

• 2 novel antibody drugs approved for the first time in Q3

• Top 10 antibody drug deals, including acquisitions, licensing agreements, and collaborations of up to US$8B

• Current research into designing antibodies from scratch (de novo)

• Immune cell engagers as a bispecific antibody format

• A list of antibody drugs with soon approaching approval action dates to keep an eye out for in Q4 2025

Register now for a free download of the report!